nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0746	0.115	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0746	0.115	CbGbCtD
Ondansetron—CYP2E1—Dacarbazine—peripheral nervous system neoplasm	0.0619	0.0956	CbGbCtD
Ondansetron—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.056	0.0864	CbGbCtD
Ondansetron—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0448	0.0692	CbGbCtD
Ondansetron—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0375	0.058	CbGbCtD
Ondansetron—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0358	0.0553	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0343	0.0529	CbGbCtD
Ondansetron—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0343	0.0529	CbGbCtD
Ondansetron—CYP2E1—Etoposide—peripheral nervous system neoplasm	0.0303	0.0468	CbGbCtD
Ondansetron—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0257	0.0397	CbGbCtD
Ondansetron—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0235	0.0364	CbGbCtD
Ondansetron—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0235	0.0363	CbGbCtD
Ondansetron—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0218	0.0337	CbGbCtD
Ondansetron—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0175	0.0271	CbGbCtD
Ondansetron—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0161	0.0248	CbGbCtD
Ondansetron—HTR1B—dura mater—peripheral nervous system neoplasm	0.0159	0.228	CbGeAlD
Ondansetron—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.01	0.0155	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00985	0.0152	CbGbCtD
Ondansetron—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00918	0.0142	CbGbCtD
Ondansetron—HTR3A—vagus nerve—peripheral nervous system neoplasm	0.00763	0.109	CbGeAlD
Ondansetron—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.00684	0.0979	CbGeAlD
Ondansetron—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00626	0.00967	CbGbCtD
Ondansetron—HTR3A—cranial nerve—peripheral nervous system neoplasm	0.00581	0.0831	CbGeAlD
Ondansetron—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.00487	0.0698	CbGeAlD
Ondansetron—HTR3A—nerve—peripheral nervous system neoplasm	0.00298	0.0426	CbGeAlD
Ondansetron—HTR3A—ganglion—peripheral nervous system neoplasm	0.00294	0.0421	CbGeAlD
Ondansetron—OPRM1—nerve—peripheral nervous system neoplasm	0.00273	0.0391	CbGeAlD
Ondansetron—OPRM1—ganglion—peripheral nervous system neoplasm	0.0027	0.0386	CbGeAlD
Ondansetron—HTR1B—ganglion—peripheral nervous system neoplasm	0.00247	0.0353	CbGeAlD
Ondansetron—HTR1A—ganglion—peripheral nervous system neoplasm	0.00199	0.0285	CbGeAlD
Ondansetron—HTR3A—trigeminal ganglion—peripheral nervous system neoplasm	0.00144	0.0207	CbGeAlD
Ondansetron—SLC47A1—trigeminal ganglion—peripheral nervous system neoplasm	0.00142	0.0203	CbGeAlD
Ondansetron—HTR3A—brainstem—peripheral nervous system neoplasm	0.00128	0.0183	CbGeAlD
Ondansetron—SLC47A1—brainstem—peripheral nervous system neoplasm	0.00126	0.018	CbGeAlD
Ondansetron—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.00121	0.0173	CbGeAlD
Ondansetron—OPRM1—brainstem—peripheral nervous system neoplasm	0.00117	0.0168	CbGeAlD
Ondansetron—HTR1B—brainstem—peripheral nervous system neoplasm	0.00107	0.0153	CbGeAlD
Ondansetron—KCNH2—trigeminal ganglion—peripheral nervous system neoplasm	0.000871	0.0125	CbGeAlD
Ondansetron—HTR1A—brainstem—peripheral nervous system neoplasm	0.000865	0.0124	CbGeAlD
Ondansetron—SLC47A1—cerebellum—peripheral nervous system neoplasm	0.000619	0.00886	CbGeAlD
Ondansetron—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00047	0.00672	CbGeAlD
Ondansetron—HTR1A—cerebellum—peripheral nervous system neoplasm	0.000427	0.00611	CbGeAlD
Ondansetron—KCNH2—cerebellum—peripheral nervous system neoplasm	0.00038	0.00544	CbGeAlD
Ondansetron—CYP2E1—cerebellum—peripheral nervous system neoplasm	0.000293	0.00419	CbGeAlD
Ondansetron—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.00094	CcSEcCtD
Ondansetron—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.00026	0.000939	CcSEcCtD
Ondansetron—Ill-defined disorder—Etoposide—peripheral nervous system neoplasm	0.00026	0.000938	CcSEcCtD
Ondansetron—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000259	0.000936	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000259	0.000933	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000258	0.000932	CcSEcCtD
Ondansetron—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000258	0.00093	CcSEcCtD
Ondansetron—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000257	0.000928	CcSEcCtD
Ondansetron—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000256	0.000922	CcSEcCtD
Ondansetron—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000256	0.000922	CcSEcCtD
Ondansetron—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000253	0.000915	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000253	0.000913	CcSEcCtD
Ondansetron—Malaise—Etoposide—peripheral nervous system neoplasm	0.000253	0.000912	CcSEcCtD
Ondansetron—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000253	0.000911	CcSEcCtD
Ondansetron—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000251	0.000904	CcSEcCtD
Ondansetron—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000251	0.000904	CcSEcCtD
Ondansetron—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.00025	0.000901	CcSEcCtD
Ondansetron—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00025	0.000901	CcSEcCtD
Ondansetron—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.00025	0.000901	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—peripheral nervous system neoplasm	0.000249	0.0009	CcSEcCtD
Ondansetron—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000248	0.000894	CcSEcCtD
Ondansetron—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000246	0.000889	CcSEcCtD
Ondansetron—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000246	0.000887	CcSEcCtD
Ondansetron—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000246	0.000887	CcSEcCtD
Ondansetron—Rash—Topotecan—peripheral nervous system neoplasm	0.000246	0.000886	CcSEcCtD
Ondansetron—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000245	0.000886	CcSEcCtD
Ondansetron—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000245	0.000883	CcSEcCtD
Ondansetron—Cough—Etoposide—peripheral nervous system neoplasm	0.000245	0.000882	CcSEcCtD
Ondansetron—Headache—Topotecan—peripheral nervous system neoplasm	0.000244	0.000881	CcSEcCtD
Ondansetron—Rash—Tretinoin—peripheral nervous system neoplasm	0.000244	0.000879	CcSEcCtD
Ondansetron—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000244	0.000879	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000244	0.000879	CcSEcCtD
Ondansetron—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000244	0.000879	CcSEcCtD
Ondansetron—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000244	0.000879	CcSEcCtD
Ondansetron—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000244	0.000879	CcSEcCtD
Ondansetron—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000243	0.000878	CcSEcCtD
Ondansetron—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000243	0.000876	CcSEcCtD
Ondansetron—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000243	0.000875	CcSEcCtD
Ondansetron—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000242	0.000875	CcSEcCtD
Ondansetron—Headache—Tretinoin—peripheral nervous system neoplasm	0.000242	0.000874	CcSEcCtD
Ondansetron—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000242	0.000874	CcSEcCtD
Ondansetron—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000241	0.000871	CcSEcCtD
Ondansetron—Pain—Vincristine—peripheral nervous system neoplasm	0.000241	0.000871	CcSEcCtD
Ondansetron—Constipation—Vincristine—peripheral nervous system neoplasm	0.000241	0.000871	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.000241	0.000869	CcSEcCtD
Ondansetron—Rash—Melphalan—peripheral nervous system neoplasm	0.000241	0.000868	CcSEcCtD
Ondansetron—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00024	0.000867	CcSEcCtD
Ondansetron—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00024	0.000864	CcSEcCtD
Ondansetron—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000239	0.000861	CcSEcCtD
Ondansetron—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000237	0.000856	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000237	0.000855	CcSEcCtD
Ondansetron—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000236	0.00085	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000235	0.000847	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000235	0.000847	CcSEcCtD
Ondansetron—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000233	0.000842	CcSEcCtD
Ondansetron—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000233	0.00084	CcSEcCtD
Ondansetron—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000233	0.00084	CcSEcCtD
Ondansetron—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000232	0.00331	CbGeAlD
Ondansetron—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000232	0.000836	CcSEcCtD
Ondansetron—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000232	0.000836	CcSEcCtD
Ondansetron—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000231	0.000833	CcSEcCtD
Ondansetron—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000229	0.000825	CcSEcCtD
Ondansetron—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000227	0.000818	CcSEcCtD
Ondansetron—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000813	CcSEcCtD
Ondansetron—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000224	0.000809	CcSEcCtD
Ondansetron—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000223	0.000805	CcSEcCtD
Ondansetron—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000223	0.000805	CcSEcCtD
Ondansetron—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000223	0.000805	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000223	0.000804	CcSEcCtD
Ondansetron—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000223	0.000803	CcSEcCtD
Ondansetron—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000222	0.000801	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000792	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000792	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000217	0.000784	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000217	0.000784	CcSEcCtD
Ondansetron—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000216	0.00078	CcSEcCtD
Ondansetron—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000216	0.000779	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000216	0.000777	CcSEcCtD
Ondansetron—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000214	0.000771	CcSEcCtD
Ondansetron—Pain—Cisplatin—peripheral nervous system neoplasm	0.000213	0.00077	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000211	0.00076	CcSEcCtD
Ondansetron—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00021	0.000758	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.000752	CcSEcCtD
Ondansetron—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000208	0.00075	CcSEcCtD
Ondansetron—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000207	0.000748	CcSEcCtD
Ondansetron—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000206	0.000742	CcSEcCtD
Ondansetron—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000205	0.000741	CcSEcCtD
Ondansetron—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000204	0.000736	CcSEcCtD
Ondansetron—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000203	0.000733	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.000733	CcSEcCtD
Ondansetron—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000203	0.000731	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000725	CcSEcCtD
Ondansetron—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000201	0.000725	CcSEcCtD
Ondansetron—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.0002	0.000723	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000719	CcSEcCtD
Ondansetron—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000199	0.000719	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000197	0.000712	CcSEcCtD
Ondansetron—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000197	0.000712	CcSEcCtD
Ondansetron—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000197	0.000711	CcSEcCtD
Ondansetron—Constipation—Etoposide—peripheral nervous system neoplasm	0.000196	0.000706	CcSEcCtD
Ondansetron—Pain—Etoposide—peripheral nervous system neoplasm	0.000196	0.000706	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000705	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000704	CcSEcCtD
Ondansetron—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000194	0.000699	CcSEcCtD
Ondansetron—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000193	0.000697	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000686	CcSEcCtD
Ondansetron—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000188	0.00068	CcSEcCtD
Ondansetron—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000187	0.000675	CcSEcCtD
Ondansetron—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000187	0.000673	CcSEcCtD
Ondansetron—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000186	0.000672	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000671	CcSEcCtD
Ondansetron—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000185	0.000666	CcSEcCtD
Ondansetron—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000185	0.000666	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000665	CcSEcCtD
Ondansetron—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000184	0.000664	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000663	CcSEcCtD
Ondansetron—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000184	0.000662	CcSEcCtD
Ondansetron—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000182	0.000655	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000654	CcSEcCtD
Ondansetron—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000181	0.000652	CcSEcCtD
Ondansetron—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000181	0.000652	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000652	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.00018	0.000651	CcSEcCtD
Ondansetron—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000179	0.000648	CcSEcCtD
Ondansetron—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000179	0.000646	CcSEcCtD
Ondansetron—Rash—Vincristine—peripheral nervous system neoplasm	0.000178	0.000642	CcSEcCtD
Ondansetron—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000178	0.000642	CcSEcCtD
Ondansetron—Headache—Vincristine—peripheral nervous system neoplasm	0.000177	0.000638	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000635	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000627	CcSEcCtD
Ondansetron—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000171	0.000616	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000615	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000613	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000608	CcSEcCtD
Ondansetron—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000168	0.000608	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000605	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000604	CcSEcCtD
Ondansetron—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000604	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000602	CcSEcCtD
Ondansetron—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000164	0.000592	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000164	0.000591	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000163	0.000588	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000163	0.000587	CcSEcCtD
Ondansetron—Chills—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000584	CcSEcCtD
Ondansetron—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000162	0.000584	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000161	0.000582	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.00058	CcSEcCtD
Ondansetron—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000159	0.000573	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000569	CcSEcCtD
Ondansetron—Rash—Cisplatin—peripheral nervous system neoplasm	0.000157	0.000568	CcSEcCtD
Ondansetron—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000157	0.000567	CcSEcCtD
Ondansetron—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000567	CcSEcCtD
Ondansetron—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000156	0.000564	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000563	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000559	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000559	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000558	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000546	CcSEcCtD
Ondansetron—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000151	0.000546	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000544	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000543	CcSEcCtD
Ondansetron—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.00054	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000538	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000534	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000526	CcSEcCtD
Ondansetron—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000145	0.000525	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000524	CcSEcCtD
Ondansetron—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000521	CcSEcCtD
Ondansetron—Rash—Etoposide—peripheral nervous system neoplasm	0.000144	0.00052	CcSEcCtD
Ondansetron—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000144	0.00052	CcSEcCtD
Ondansetron—Headache—Etoposide—peripheral nervous system neoplasm	0.000143	0.000517	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000517	CcSEcCtD
Ondansetron—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000511	CcSEcCtD
Ondansetron—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000508	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000501	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000498	CcSEcCtD
Ondansetron—Cough—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000494	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000494	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000491	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000486	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000482	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000482	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000481	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000479	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000477	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000473	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000472	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.00047	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000463	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000462	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000461	CcSEcCtD
Ondansetron—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000458	CcSEcCtD
Ondansetron—Shock—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000455	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000454	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000454	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000451	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000449	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000446	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000445	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000443	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000441	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000437	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000432	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000428	CcSEcCtD
Ondansetron—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000421	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.00042	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000418	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000416	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000415	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000412	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000411	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.0004	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000399	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000399	CcSEcCtD
Ondansetron—Constipation—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000395	CcSEcCtD
Ondansetron—Pain—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000395	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000384	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000382	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000381	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.00038	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000378	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000369	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000369	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000367	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000366	CcSEcCtD
Ondansetron—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000366	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000366	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000366	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	9.77e-05	0.000353	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	9.7e-05	0.00035	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	9.44e-05	0.000341	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—peripheral nervous system neoplasm	9.42e-05	0.00034	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	9.38e-05	0.000338	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	9.38e-05	0.000338	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—peripheral nervous system neoplasm	9.2e-05	0.000332	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—peripheral nervous system neoplasm	9.07e-05	0.000327	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	8.77e-05	0.000316	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	8.74e-05	0.000315	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—peripheral nervous system neoplasm	8.51e-05	0.000307	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—peripheral nervous system neoplasm	8.48e-05	0.000306	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—peripheral nervous system neoplasm	8.39e-05	0.000303	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—peripheral nervous system neoplasm	8.15e-05	0.000294	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	8.12e-05	0.000293	CcSEcCtD
Ondansetron—Rash—Epirubicin—peripheral nervous system neoplasm	8.08e-05	0.000292	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—peripheral nervous system neoplasm	8.08e-05	0.000291	CcSEcCtD
Ondansetron—Headache—Epirubicin—peripheral nervous system neoplasm	8.03e-05	0.00029	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—peripheral nervous system neoplasm	7.84e-05	0.000283	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—peripheral nervous system neoplasm	7.54e-05	0.000272	CcSEcCtD
Ondansetron—Rash—Doxorubicin—peripheral nervous system neoplasm	7.48e-05	0.00027	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	7.47e-05	0.00027	CcSEcCtD
Ondansetron—Headache—Doxorubicin—peripheral nervous system neoplasm	7.43e-05	0.000268	CcSEcCtD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	2.71e-05	0.00501	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—BCHE—peripheral nervous system neoplasm	2.64e-05	0.00488	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	2.61e-05	0.00482	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.58e-05	0.00477	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.54e-05	0.00469	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—PTPN11—peripheral nervous system neoplasm	2.53e-05	0.00468	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	2.5e-05	0.00462	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	2.48e-05	0.00459	CbGpPWpGaD
Ondansetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	2.36e-05	0.00437	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	2.32e-05	0.00429	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	2.29e-05	0.00424	CbGpPWpGaD
Ondansetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	2.25e-05	0.00416	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	2.25e-05	0.00416	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	2.19e-05	0.00405	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	2.16e-05	0.00399	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.14e-05	0.00396	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.08e-05	0.00384	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.05e-05	0.0038	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.04e-05	0.00377	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	2.02e-05	0.00374	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.96e-05	0.00361	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	1.93e-05	0.00357	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	1.92e-05	0.00354	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.79e-05	0.00332	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	1.74e-05	0.00322	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	1.69e-05	0.00313	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	1.67e-05	0.00309	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	1.67e-05	0.00308	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.66e-05	0.00308	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.63e-05	0.00301	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.62e-05	0.003	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	1.61e-05	0.00298	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.57e-05	0.00291	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.57e-05	0.0029	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.54e-05	0.00285	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	1.54e-05	0.00284	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	1.52e-05	0.0028	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.5e-05	0.00277	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	1.47e-05	0.00272	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	1.46e-05	0.0027	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	1.45e-05	0.00268	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.42e-05	0.00263	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	1.34e-05	0.00247	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	1.33e-05	0.00245	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.33e-05	0.00245	CbGpPWpGaD
Ondansetron—OPRM1—IL4-mediated signaling events—AKT1—peripheral nervous system neoplasm	1.33e-05	0.00245	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.29e-05	0.00238	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	1.28e-05	0.00237	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	1.27e-05	0.00235	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.26e-05	0.00234	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.21e-05	0.00223	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.2e-05	0.00222	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.17e-05	0.00216	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.16e-05	0.00214	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	1.15e-05	0.00213	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.15e-05	0.00212	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.13e-05	0.00208	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.12e-05	0.00208	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.12e-05	0.00206	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—HRAS—peripheral nervous system neoplasm	1.11e-05	0.00206	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	1.11e-05	0.00205	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.1e-05	0.00203	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.06e-05	0.00196	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.02e-05	0.00189	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.01e-05	0.00187	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.01e-05	0.00187	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	1.01e-05	0.00187	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	9.9e-06	0.00183	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—AKT1—peripheral nervous system neoplasm	9.84e-06	0.00182	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	9.76e-06	0.0018	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	9.63e-06	0.00178	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KNG1—peripheral nervous system neoplasm	9.63e-06	0.00178	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	9.35e-06	0.00173	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.17e-06	0.0017	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	9.09e-06	0.00168	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	8.95e-06	0.00165	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	8.84e-06	0.00163	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	8.75e-06	0.00162	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	8.58e-06	0.00159	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.55e-06	0.00158	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.48e-06	0.00157	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.42e-06	0.00156	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.14e-06	0.0015	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GNS—peripheral nervous system neoplasm	8.12e-06	0.0015	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.12e-06	0.0015	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	8.07e-06	0.00149	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.9e-06	0.00146	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NME1—peripheral nervous system neoplasm	7.79e-06	0.00144	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.57e-06	0.0014	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—COX2—peripheral nervous system neoplasm	7.5e-06	0.00139	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	7.5e-06	0.00139	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.24e-06	0.00134	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	7.14e-06	0.00132	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.82e-06	0.00126	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.81e-06	0.00126	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.78e-06	0.00125	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.62e-06	0.00122	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	6.56e-06	0.00121	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.54e-06	0.00121	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.26e-06	0.00116	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—HRAS—peripheral nervous system neoplasm	6.2e-06	0.00115	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.01e-06	0.00111	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.99e-06	0.00111	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.95e-06	0.0011	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.95e-06	0.0011	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GNS—peripheral nervous system neoplasm	5.89e-06	0.00109	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	5.87e-06	0.00109	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.85e-06	0.00108	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.79e-06	0.00107	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.78e-06	0.00107	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.73e-06	0.00106	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.71e-06	0.00106	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NME1—peripheral nervous system neoplasm	5.64e-06	0.00104	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	5.63e-06	0.00104	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.59e-06	0.00103	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.52e-06	0.00102	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—COX2—peripheral nervous system neoplasm	5.43e-06	0.001	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	5.42e-06	0.001	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.25e-06	0.000971	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.19e-06	0.000959	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.17e-06	0.000955	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	4.99e-06	0.000923	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ENO2—peripheral nervous system neoplasm	4.92e-06	0.00091	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.89e-06	0.000904	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.77e-06	0.000881	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.76e-06	0.00088	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.7e-06	0.000869	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.62e-06	0.000855	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.54e-06	0.000838	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.36e-06	0.000805	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.24e-06	0.000783	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.2e-06	0.000776	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	4.18e-06	0.000772	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—BCHE—peripheral nervous system neoplasm	4.16e-06	0.000769	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.15e-06	0.000767	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	4.14e-06	0.000765	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.14e-06	0.000765	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.07e-06	0.000752	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.02e-06	0.000743	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	4e-06	0.00074	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	3.97e-06	0.000734	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.97e-06	0.000733	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	3.91e-06	0.000723	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	3.85e-06	0.000712	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.85e-06	0.000711	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.83e-06	0.000708	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	3.82e-06	0.000706	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.78e-06	0.000698	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.65e-06	0.000675	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.58e-06	0.000662	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ENO2—peripheral nervous system neoplasm	3.57e-06	0.000659	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	3.56e-06	0.000658	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.55e-06	0.000656	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	3.54e-06	0.000654	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.52e-06	0.00065	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.52e-06	0.00065	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.39e-06	0.000627	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.38e-06	0.000625	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.28e-06	0.000606	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	3.27e-06	0.000603	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	3.19e-06	0.00059	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.15e-06	0.000583	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	3.13e-06	0.000579	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.1e-06	0.000574	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.06e-06	0.000566	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—BCHE—peripheral nervous system neoplasm	3.01e-06	0.000557	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	3.01e-06	0.000556	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.92e-06	0.00054	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.87e-06	0.000531	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.87e-06	0.00053	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TH—peripheral nervous system neoplasm	2.83e-06	0.000524	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	2.83e-06	0.000522	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	2.73e-06	0.000505	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.69e-06	0.000497	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.68e-06	0.000495	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	2.62e-06	0.000484	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.57e-06	0.000476	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	2.53e-06	0.000468	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.52e-06	0.000466	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	2.51e-06	0.000464	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.49e-06	0.00046	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.44e-06	0.000452	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GNAS—peripheral nervous system neoplasm	2.31e-06	0.000427	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	2.31e-06	0.000427	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.27e-06	0.00042	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.27e-06	0.000419	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	2.26e-06	0.000419	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.2e-06	0.000406	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.16e-06	0.000399	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	2.14e-06	0.000396	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	2.14e-06	0.000395	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	2.12e-06	0.000392	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.04e-06	0.000377	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.02e-06	0.000374	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	2.01e-06	0.000372	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	1.99e-06	0.000368	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.93e-06	0.000357	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.9e-06	0.00035	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.86e-06	0.000344	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.82e-06	0.000336	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.81e-06	0.000335	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.77e-06	0.000327	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.75e-06	0.000324	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.73e-06	0.000319	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.7e-06	0.000315	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.7e-06	0.000315	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.65e-06	0.000306	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	1.64e-06	0.000303	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.63e-06	0.000301	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	1.61e-06	0.000298	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.61e-06	0.000297	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.61e-06	0.000297	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.6e-06	0.000295	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.56e-06	0.000289	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.55e-06	0.000286	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.47e-06	0.000272	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.47e-06	0.000272	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.42e-06	0.000262	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.4e-06	0.000258	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.39e-06	0.000257	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.39e-06	0.000256	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.37e-06	0.000253	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.36e-06	0.000252	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.35e-06	0.000249	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.34e-06	0.000247	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.33e-06	0.000246	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.31e-06	0.000243	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.3e-06	0.00024	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.22e-06	0.000226	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.21e-06	0.000223	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.12e-06	0.000208	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.12e-06	0.000207	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.08e-06	0.000199	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.07e-06	0.000198	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.05e-06	0.000195	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.04e-06	0.000193	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.92e-07	0.000183	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.49e-07	0.000175	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.49e-07	0.000175	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	8.62e-07	0.000159	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.56e-07	0.000158	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.38e-07	0.000155	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.19e-07	0.000151	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.23e-07	0.000134	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—peripheral nervous system neoplasm	6.24e-07	0.000115	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	6.23e-07	0.000115	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	4.43e-07	8.19e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	4.39e-07	8.12e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.75e-07	6.94e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.9e-07	5.35e-05	CbGpPWpGaD
